#TBT An absolute honor to have Prof. Dr. Huda Zoghbi, MD as my mentor for my Basic Science Lecture on Rett Syndrome and MECP2 Duplication Syndrome! @TexasChildrens @HMHNeurology 🧠

Using high-throughput PhIP-Seq, we identified NPAS4-IgG, a novel autoantibody in CSF of antibody-negative autoimmune limbic encephalitis & additional AK5-IgG cases, highlighting PhIP-Seq’s role in uncovering new autoimmune biomarkers#AutoimmuneEncephalitis

Sometimes all that glitters is gold 💫 In thinking of PAF as a prodromal state, we miss that the majority of patients remain PAF during their lifetime. This is an important group and we studied their clinical and autonomic profiles 🚨 Hot off the press @ClinAutonRes

When I have a new fellow or resident in our peripheral nerve clinic, I always teach them the importance of defining the neuropathy clinical syndrome. NCS/EMG are valuable, but the neurological exam is the most important (as it should be in neurology but many have forgotten).

🔔 New Study: Differential diagnosis in immune checkpoint inhibitors neurotoxicity https://t.co/FIYrqgLuga @GarcCate @timgregorymd @MDAndersonNews

Grateful to be part of this collaborative effort with Dr. John Mills and the amazing team at @MayoClinicLabs. A testament to teamwork and the lab’s continued commitment to advancing diagnostics for demyelinating neuropathies. #Neurology #Neuropathy

🔔Teaching NeuroImage: Use of Arterial Spin Labeling to Differentiate Ictal Phenomenon From Tumor Progression in Grade 3 Astrocytoma | Neurology

Our study on ANNA1 (anti-Hu) autoimmunity reveals distinct phenotypes, cancer links, and biomarkers across ages.PhIP-Seq identified phenotype specific immunosignatures, serum NfL levels correlated with poor outcomes. https://t.co/yWx2jTTGUN

🔔Check out our paper on ANNA1 Autoimmunity: ANNA1 Neurological Autoimmunity: A Comparative Analysis of Cancers, Neurological Phenotype and Coexisting Antibodies Across Age Demographics | Neurology

Our study validates the 2021 PNS-CARE score with high sensitivity (93%) and specificity (100%), improving on the 2004 criteria. We highlight key antibodies and phenotypes for earlier, accurate diagnosis. @HZhaoFleming

With the highest accuracy the biomarkers we present in this work determine whether some one benefits from radiation therapy or not - @MeningiomaBot @meningiomauk #meningioma https://t.co/kKJN62J8L9

A 61 year old man comes to see you for muscle cramps “Cramps. You mean like the kind in your calf that wake you up at night?” “No doc, they look like this…” What’s going on here??

Honored to be presenting at the ABTA National Conference next month and looking forward to connecting with the brain tumor community. See you there! https://t.co/Cm8gyxHri8 #BTSM #BrainTumorAwareness @theABTA

🗣️Come by our posters to learn more at the #AANSC @AANmember 🧠⚡️

Autoimmune‐associated seizure disorders are important to recognize! Check out this important review we put together. @JeffBrittonMD @adrianbudhram1

🥁 Excited to share our recent work on sNfL! @MDAndersonNews Cerebral clues: serum neurofilament light chain (sNfL) as a novel biomarker for immune check point inhibitor (ICI) mediated seronegative encephalitis

Dr. @J_deGrootMD, Chief of Neuro-Oncology at @UCSF, Arm Co-PI of VAL-083 and GBM AGILE Arm Selection Committee Member presented results of the VAL-083 experimental arm of #GBMAGILE at #ASCO24 Key takeaways- - GBM AGILE is a global adaptive platform trial designed to rapidly

Brachial amyotrophic diplegia isn't just linked to ALS. Our study reveals paraneoplastic autoimmunity as a possible cause, highlighted by LUZP4-IgG and KLHL11-IgG seropositivity, alongside associated clinical features like ataxia, vertigo, and hearing loss https://t.co/xDHc2WVvJk

MRI, EEG, EMG, LP. The beauty and pain of neurology is that with these - unless you do a great history (when)/exam (where) - 50% of the time you will still have no idea what is going on. There is no test (yet) that can replace your friendly (mostly) neighborhood neurologist.

Fantastic News! I am ever grateful to learn from Dr. Wszolek on our case collaboration @MayoClinicNeuro sharing soon.. 📢Interim Results on VGL101 from IGNITE: First Interventional Phase 2 Study in Patients with Adultonset Leukoencephalopathy | Neurology

Upadhya et al. show that antibodies against LGI1 from patients with limbic encephalitis cause seizures in a laboratory model, adding to evidence for a causal role of LGI1 antibodies in seizure generation. https://t.co/89EtKaZIQA